Management of hemosiderosis complicated by coexistent anemia with recombinant human erythropoietin and phlebotomy.
Patients with hemosiderosis who also suffer from coexistent anemia may be unable to tolerate frequent phlebotomies needed for depletion of body iron stores. Chelation therapy, an alternative approach, may be unsuitable for some patients due to allergic reactions, poor response or intolerance of long-duration subcutaneous administration. The use of recombinant human erythropoietin in such patients could increase the hematocrit and improve exercise tolerance allowing for more frequent phlebotomies. We report the successful use of this combined approach in two such patients.
Bilgrami
S
S
Division of Hematology-Oncology, University of Connecticut, School of Medicine, Farmington.
Bartolomeo
A
A
Synnott
V
V
Rickles
F R
FR
D000368:Aged; D000753:Anemia, Refractory / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D001815:Bloodletting; D003131:Combined Modality Therapy; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006486:Hemosiderosis / Q000150:complications / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin